ONYX PHARMACEUTICALS $96.20

up +3.17


23/5/2013 04:23 PM  |  NASDAQ : ONXX  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 125% - ONXX has outperformed the S&P 500 by 99%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga

  2. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga

  3. Onyx Pharmaceuticals Announces 4.4M Share Public Offering of ...

    Benzinga

  4. Onyx Pharma Will Offer 4.4M Shares

    Benzinga

  5. Onyx Pharmaceuticals, Inc. (ONXX) EVP & CFO Matthew K Fust sells ...

    GuruFocus

  6. Onyx Pharmaceuticals Announces 2013 Updates, 2012 Achievements at ...

    Benzinga

  7. Phase 3 DECISION Trial of Nexavar Meets Primary Endpoint

    Benzinga

  8. UPDATE: Bank of America Maintains Onyx Pharmaceuticals at Buy on ...

    Benzinga

  9. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga

  10. UPDATE: Dawson James Securities Initiates Coverage on Onyx ...

    Benzinga

  11. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga

  12. Edward Owens' Vanguard Health Care Fund Does More Shedding Than ...

    GuruFocus

  13. Celgene Earnings Beat Views; Guidance Raised A Bit

    Investors Business Daily

  14. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga

  15. Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

    Benzinga

  16. Bank of America Merrill Lynch Reiterates Buy Rating, $89 PO on ...

    Benzinga

  17. Bayer's Stivarga Tablets Approved by FDA

    Benzinga

  18. Benzinga Mid-Day Market Update

    Benzinga

  19. Short Sellers Shy Away from Biotech Firms

    Benzinga

  20. UPDATE: Maxim Group Reiterates Buy Rating, Raises PT on Onyx ...

    Benzinga

  21. Bayer Submits New Drug Application for Regorafenib for the ...

    Benzinga

  22. Health Care Sector Wrap

    FOXBusiness

  23. Short Sellers Shy Away from Biotech Firms

    Benzinga

  24. ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles ...

    GuruFocus

  25. ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 22,009 ...

    GuruFocus

  26. ONYX Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  27. ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles ...

    GuruFocus

  28. Top-Performing Funds Latch On To Biotech And Discount Retail Stocks

    Investors Business Daily

  29. ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles ...

    GuruFocus

  30. ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 5,207 Shares

    GuruFocus

  31. Biotechs In Motion As New Drug Pipeline Brims

    Investors Business Daily

  32. Celgene Reverses Bad Streak With Q2 Earnings Beat

    Investors Business Daily

  33. UPDATE: Maxim Group Reiterates Buy Rating, Raises PT on Onyx ...

    Benzinga

  34. UPDATE: Jefferies Upgrades Onyx Pharmaceuticals to Buy Post ...

    Benzinga

  35. Onyx Pharma

    Investors Business Daily

  36. Health Care Sector Wrap

    FOXBusiness

  37. Analyst Upgrades: Onyx Pharmaceuticals, Sirius XM Radio, and Zagg

    By SchaeffersResearch

  38. Onyx Pharmaceuticals Pops 12% on FDA Approval

    Benzinga

  39. PPG Industries, athenahealth Among Stocks Hitting 52-Week Highs Friday

    FOXBusiness

  40. UPDATE: Kyprolis for Injection Receives Accelerated Approval from ...

    Benzinga

  41. Biotechs With Upcoming PDUFA Dates

    Benzinga

  42. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga

  43. Onyx Pharmaceuticals Initiates Phase 3 Kyprolis™ Head-to-Head ...

    Benzinga

  44. Top 4 Mid-Cap Stocks In The Biotechnology Industry With The ...

    Benzinga

  45. Highs & Lows: Onyx Pharmaceuticals, Smart Balance, and Key Energy ...

    By SchaeffersResearch

  46. Arena Plunged After Run-up Prior To Diet Drug Ruling

    Investors Business Daily

  47. Merck &, Onyx Pharmaceuticals Among Stocks Hitting 52-Week Highs ...

    FOXBusiness

  48. Stocks Plummet as Downgrade Fears Grip the Market with Onyx ...

    At Market Intelligence Center

  49. One Drugmaker Soars, 1 Falls

    Investors Business Daily

  50. Onyx Up, Celgene Down On Cancer Drug News

    Investors Business Daily

  51. Medical Sector Shows Muscle With SXC Health, Cerner

    Investors Business Daily

  52. Stocks Lose Ground Amid Worries of Global Slowdown with Bed Bath & ...

    At Market Intelligence Center

  53. Onyx Pharmaceuticals Soars after FDA Advisory Panel Vote

    Benzinga

  54. Onyx Pharmaceuticals (ONXX) Up 36.5% After FDA Panel OKs Blood ...

    At Market Intelligence Center

  55. Winning Trades Based on Analyst Ratings for June 21

    Benzinga

  56. Thursday Market Movers (RAD, SUNH, ONXX)

    Benzinga

  57. Stocks Futures Point to a Lower Open as Global Economic Worries ...

    At Market Intelligence Center

  58. Social Media Outlook for Thursday June 21 (KBALB, ONXX, BBBY, DECK)

    Benzinga

  59. UPDATE: Morgan Stanley Upgrades Onyx Pharmaceuticals

    Benzinga

  60. UPDATE: J.P. Morgan Raises PT on Onyx Pharmaceuticals to $66

    Benzinga

  61. UPDATE: Jefferies raises PT on Onyx Pharmaceuticals to $55

    Benzinga

  62. FDA Advisory Panel Approves Onyx Blood Cancer Drug

    Investors Business Daily

  63. Top Narrow Based Indexes For June 21

    Benzinga

  64. Morning Market Movers

    Benzinga

  65. UPDATE: Maxim Group Raises PT to $75 on Onyx Pharmaceuticals as ...

    Benzinga

  66. UPDATE: Rodman & Renshaw Raises PT to $73 on Onyx Pharmaceuticals ...

    Benzinga

  67. Benzinga's Top Upgrades

    Benzinga

  68. Financial Breakfast: Morning News Summary for June 21, 2012

    Benzinga

  69. Onyx Pharma Gets Positive Vote for Kyprolis from Oncologic Drugs ...

    Benzinga

  70. UPDATE: Trading Of Onyx Pharmaceuticals Common Stock Halted; ...

    Benzinga

  71. Social Media Outlook for Tuesday June 19 (IDCC, ABT, ONXX, BODY)

    Benzinga

  72. Stocks Mixed on Growing Europe Woes with Morgan Stanley (MS) and ...

    At Market Intelligence Center

  73. Drug-Related News Derails Onyx Pharmaceuticals' Momentum

    By SchaeffersResearch

  74. Onyx Pharmaceuticals (ONXX) Up 0.8% in Volitile Trade as Data ...

    At Market Intelligence Center

  75. Onyx Pharmaceuticals (ONXX) Up 7.6% after Bank of America-Merrill ...

    At Market Intelligence Center

  76. UPDATE: Bank of America Upgrades Onyx Pharmaceuticals to Buy on ...

    Benzinga

  77. Financial Breakfast: Morning News Summary for June 8, 2012

    Benzinga

  78. Drug Stocks In The Spotlight At Cancer Conference

    Investors Business Daily

  79. New Drug Application for Regorafenib for the Treatment of ...

    Benzinga

  80. Stocks Set for Flat Open as Global Economic Worries Rise with Best ...

    At Market Intelligence Center

  81. From Earlier: Phase 3 MISSION trial of Nexavar in Patients with ...

    Benzinga

  82. Benzinga's Top Pre-Market Gainers

    Benzinga

  83. Onyx Pharmaceuticals (ONXX) Hits New High on Health Care Debate, ...

    At Market Intelligence Center

  84. Notable Call Options Activity in Onyx Pharmaceuticals

    at Benzinga

  85. Morgan Stanley Initiates Coverage on Onyx Pharmaceuticals at ...

    at Benzinga

  86. 5 Inexpensive Stocks for Your Portfolio

    at GuruFocus

  87. Rodman & Renshaw Maintains Outperform, $57 PT on Onyx

    at Benzinga

  88. Rodman & Renshaw Maintains Outperform, $57 Target on ONYX ...

    at Benzinga

  89. ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 1,789 Shares

    at GuruFocus

  90. Jefferies Downgrades Onyx Pharmaceuticals to Hold

    at Benzinga

  91. Onyx Pharmaceuticals (ONXX) Gains 2.8% after Bristol Myers (BMY) ...

    At Market Intelligence Center

  92. Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure

    at Benzinga

  93. Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals

    at Benzinga

  94. Benzinga's M&A Chatter for Thursday December 15, 2011

    at Benzinga

  95. Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy

    at Benzinga

  96. Brean Murray Carret & Company Maintains Hold on Onyx Pharmaceuticals

    at Benzinga

  97. Onyx declines on FDA delay

    at IBD

  98. Onyx Pharmaceuticals (ONXX) Drops 5.2% after FDA Passes on ...

    At Market Intelligence Center

  99. UPDATE: Goldman Sachs Reiterates Buy, Lowers PT $45 on Onyx ...

    at Benzinga

  100. JP Morgan Maintains Overweight on Onyx Pharmaceuticals

    at Benzinga
People viewing ONXX also viewed: , , , , , ,
Marketplace
Trading Center